nach oben

Erschienen in:

01.07.2011 | Original Article

Transient Myeloproliferative Disorder and GATA1 Mutation in Neonates With and Without Down Syndrome

verfasst von: Ming-Horng Tsai, Jia-Woei Hou, Chao-Ping Yang, Pong-Hong Yang, Shih-Ming Chu, Jen-Fu Hsu, Ming-Chou Chiang, Hsuan-Rong Huang

Erschienen in: Indian Journal of Pediatrics | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

To report clinical experiences and cytogenetic findings of transient myeloproliferative disorder (TMD) in neonates with and without Down syndrome (DS).

Methods

GATA1 gene was screened in DNA samples from neonates presenting with TMD during their leukemic and remission status.

Results

Six neonates (2 phenotypically normal and 4 DS) born in the past 6 years had presented with TMD; all had trisomy 21 during leukemic status. Two DS infants died during early infancy, one of hepatic failure and one of cardiac complication. One non-DS infant evolved into myelodysplastic syndrome (MDS) and acute leukemia since 14 months old. Three other patients have not developed true leukemia after follow-up of 8, 9, and 70 months, respectively. The authors detected mutations within exon 2 of GATA1 gene in 3 DS and 2 non-DS infants. All these mutations disappeared after remission of TMD, but an identical mutation was detected in one non-DS patient when evolving into MDS. Trisomy 21 was confined to leukemic clone in non-DS patients.

Conclusions

TMD should be considered in case of congenital leukemia with megakaryoblastic features and accompanied by trisomy 21 and GATA1 mutation. Both DS and non-DS patients will possibly develop true leukemia within few years.

Massey GV. Transient leukemia in newborns with Down syndrome. Pediatr Blood Cancer. 2005;44:29–32.PubMedCrossRef

Schunk GJ, Lehman WL. Mongolism and congenital leukemia. JAMA. 1954;155:250–1.

Engel R, Hammond D. Transient congenital leukemia in 7 infants with mongolism. J Pediatr. 1964;65:303–5.PubMedCrossRef

Magalhães IQ, Splendore A, Emerenciano M, et al. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol. 2005;27:50–2.PubMedCrossRef

Cushing T, Clericuzio CL, Wilson CS, et al. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr. 2006;148:687–9.PubMedCrossRef

Brissette MD, Duval-Arnould BJ, Gordon BG, Cotelingam JD. Acute megakaryoblastic leukemia following transient myeloproliferative disorder in a patient without Down syndrome. Am J Hematol. 1994;47:316–9.PubMedCrossRef

Richards M, Welch J, Watmore A, Readett D, Vora AJ. Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down’s syndrome. Arch Dis Child Fetal Neonatal Ed. 1998;79:F215–217.PubMedCrossRef

Crispino JD. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer. 2005;44:40–4.PubMedCrossRef

Gassas A, Doyle JJ, Weitzman S, et al. A basic classification and a comprehensive pediatric myeloproliferative disorder. J Pediatr Hematol Oncol. 2005;27:192–6.PubMedCrossRef

10.

Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): a Children’s Oncology Group (COG) study POG-9481. Blood. 2006;107:4606–13.PubMedCrossRef

11.

Vyas P, Crispino JD. Molecular insights into Down syndrome-associated leukemia. Curr Opin Pediatr. 2007;19:9–14.PubMedCrossRef

12.

Greene ME, Mundschau G, Wechsler J, et al. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003;31:351–6.PubMedCrossRef

13.

Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480–9.PubMedCrossRef

14.

Zipursky A, Brown EJ, Christensen H, Doyle J. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clin Lab Med. 1999;19:157–67.PubMed

15.

Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukemia and solid tumors in individuals with Down’s syndrome. Lancet. 2000;355:165–9.PubMedCrossRef

16.

Massey GV. Transient leukemia in newborns with Down syndrome. Pediatr Blood Cancer. 2005;44:29–32.PubMedCrossRef

17.

Brink DS. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol. 2006;13:256–62.PubMedCrossRef

18.

Zipursky A, Brown E, Christensen H, Sutherland R, Doyle J. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol. 1997;21:97–101.PubMedCrossRef

19.

Adam M, Vincenot A, Gouraud F, et al. Transient myeloproliferative disorder in a neonate without Down syndrome. Ann Biol Clin (Paris). 2007;65:569–73.

20.

Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–52.PubMedCrossRef

21.

Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613–9.PubMedCrossRef

22.

Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood. 2005;106:1223–31.PubMedCrossRef

23.

Carpenter E, Valverde-Garduno V, Sternberg A, Mitchell C, Roberts I, Vyas R. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol. 2005;128:548–51.PubMedCrossRef

24.

Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004;103:399–406.PubMedCrossRef

25.

Xu G, Kato K, Toki T, Yoshihiro T, Kiminori T, Ito E. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder. J Pediatr Hematol Oncol. 2006;28:696–8.PubMedCrossRef

26.

Chou ST, Opalinska JB, Yao Y, et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 2008;112:4503–6.PubMedCrossRef

27.

Stark B, Jeison M, Preudhomme C, et al. Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins. Br J Haematol. 2002;118:1082–6.PubMedCrossRef

28.

Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981–6.PubMedCrossRef

29.

Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007;110:2128–31.PubMedCrossRef

30.

Shin MG, Choi HW, Kim HR, et al. Tetrasomy 21 as a sole acquired abnormality without GATA1 gene mutation in pediatric acute megakaryoblastic leukemia: a case report and review of the literature. Leuk Res. 2008;32:1615–9.PubMedCrossRef

Titel: Transient Myeloproliferative Disorder and GATA1 Mutation in Neonates With and Without Down Syndrome
verfasst von: Ming-Horng Tsai
Jia-Woei Hou
Chao-Ping Yang
Pong-Hong Yang
Shih-Ming Chu
Jen-Fu Hsu
Ming-Chou Chiang
Hsuan-Rong Huang
Publikationsdatum: 01.07.2011
Verlag: Springer-Verlag
Erschienen in: Indian Journal of Pediatrics / Ausgabe 7/2011
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI: https://doi.org/10.1007/s12098-010-0312-x

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Transient Myeloproliferative Disorder and GATA1 Mutation in Neonates With and Without Down Syndrome